Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
Calcitonin gene-related peptide (CGRP) plays a key role in the pathophysiology of migraine, acting on CGRP receptors in the trigeminovascular system, causing neurogenic inflammation and vasodilation, and promoting nociception. Four specific monoclonal antibodies targeting CGRP are available for p...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/474344 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849721188683612160 |
|---|---|
| author | Davor Jančuljak Damir Petravić Darija Mahović Lakušić Arijana Lovrenčić-Huzjan Koraljka Bačić Baronica Marijana Bosnar Puretić Zlatko Hucika Marina Titlić Zvonimir Popović Zoran Tomić Maristela Stojić Vanja Bašić Kes |
| author_facet | Davor Jančuljak Damir Petravić Darija Mahović Lakušić Arijana Lovrenčić-Huzjan Koraljka Bačić Baronica Marijana Bosnar Puretić Zlatko Hucika Marina Titlić Zvonimir Popović Zoran Tomić Maristela Stojić Vanja Bašić Kes |
| author_sort | Davor Jančuljak |
| collection | DOAJ |
| description | Calcitonin gene-related peptide (CGRP) plays a key role in the pathophysiology of
migraine, acting on CGRP receptors in the trigeminovascular system, causing neurogenic inflammation
and vasodilation, and promoting nociception. Four specific monoclonal antibodies targeting CGRP
are available for prevention of episodic and chronic migraine in adults with at least four migraine
days per month. The aim of these guidelines is to provide evidence-based recommendations for the
use of monoclonal antibodies targeting CGRP in migraine prevention in Croatia. The questions were
formulated using the Patients, Intervention, Comparison, Outcome (PICO) criteria, with evidencebased
answers. To assess the quality of scientific evidence, a review of the literature available in PubMed
was performed. Relevant studies were reviewed by the Expert Group of the Headache Section of
the Croatian Neurological Society, and served as the basis for formulating the recommendations
outlined in these guidelines. We found high quality evidence for good safety and efficacy of anti-
CGRP monoclonal antibodies in the preventive treatment of episodic and chronic migraine. These
medications may be considered as first-line prophylactic therapy depending on the patient’s history,
concomitant diseases, and disease burden. Further real-world studies are needed to elucidate other
aspects of their application. |
| format | Article |
| id | doaj-art-362bb5aa0f10438e83ee0d2ba3336cd1 |
| institution | DOAJ |
| issn | 0353-9466 1333-9451 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Sestre Milosrdnice University hospital, Institute of Clinical Medical Research |
| record_format | Article |
| series | Acta Clinica Croatica |
| spelling | doaj-art-362bb5aa0f10438e83ee0d2ba3336cd12025-08-20T03:11:43ZengSestre Milosrdnice University hospital, Institute of Clinical Medical ResearchActa Clinica Croatica0353-94661333-94512024-01-0163.243644910.20471/acc.2024.63.02.22Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)Davor Jančuljak0Damir Petravić1Darija Mahović Lakušić2Arijana Lovrenčić-Huzjan3Koraljka Bačić Baronica4Marijana Bosnar Puretić5Zlatko Hucika6Marina Titlić7Zvonimir Popović8Zoran Tomić9Maristela Stojić10Vanja Bašić Kes11Department of Neurology, Osijek University Hospital Center, Osijek, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, CroatiaDepartment of Neurology, Zagreb University Hospital Center, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, CroatiaDepartment of Neurology, Zagreb University Hospital Center, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, CroatiaSchool of Medicine, University of Zagreb, Zagreb, Croatia; Department of Neurology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia; Reference Center for Headaches, Ministry of Health of the Republic of Croatia, Zagreb, CroatiaFaculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; Department of Neurology, Sveti Duh University Hospital, Zagreb, CroatiaDepartment of Neurology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; Reference Center for Headaches, Ministry of Health of the Republic of Croatia, Zagreb, Croatia; School of Medicine, Croatian Catholic University, Zagreb, Croatia; Faculty of Education and Rehabilitation Sciences, University of Zagreb, Zagreb, CroatiaDepartment of Neurology, Zabok General Hospital and Hospital for Croatian Veterans, Zabok, CroatiaDepartment of Neurology, Split University Hospital Center, Split, Croatia; School of Medicine, University of Split, Split, CroatiaDepartment of Neurology, Osijek University Hospital Center, Osijek, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, CroatiaDepartment of Neurology, Rijeka University Hospital Center, Rijeka, Croatia; School of Medicine, University of Rijeka, Rijeka, CroatiaDepartment of Neurology, Dubrava University Hospital, Zagreb, CroatiaFaculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; Department of Neurology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia; Reference Center for Headaches, Ministry of Health of the Republic of Croatia, Zagreb, CroatiaCalcitonin gene-related peptide (CGRP) plays a key role in the pathophysiology of migraine, acting on CGRP receptors in the trigeminovascular system, causing neurogenic inflammation and vasodilation, and promoting nociception. Four specific monoclonal antibodies targeting CGRP are available for prevention of episodic and chronic migraine in adults with at least four migraine days per month. The aim of these guidelines is to provide evidence-based recommendations for the use of monoclonal antibodies targeting CGRP in migraine prevention in Croatia. The questions were formulated using the Patients, Intervention, Comparison, Outcome (PICO) criteria, with evidencebased answers. To assess the quality of scientific evidence, a review of the literature available in PubMed was performed. Relevant studies were reviewed by the Expert Group of the Headache Section of the Croatian Neurological Society, and served as the basis for formulating the recommendations outlined in these guidelines. We found high quality evidence for good safety and efficacy of anti- CGRP monoclonal antibodies in the preventive treatment of episodic and chronic migraine. These medications may be considered as first-line prophylactic therapy depending on the patient’s history, concomitant diseases, and disease burden. Further real-world studies are needed to elucidate other aspects of their application.https://hrcak.srce.hr/file/474344Migraine - Prevention,TreatmentCalcitonin gene-related peptide (CGRP)Monoclonal antibodyGuidelinesEptinezumab, Fremanezumab, Galcanezumab, Erenumab |
| spellingShingle | Davor Jančuljak Damir Petravić Darija Mahović Lakušić Arijana Lovrenčić-Huzjan Koraljka Bačić Baronica Marijana Bosnar Puretić Zlatko Hucika Marina Titlić Zvonimir Popović Zoran Tomić Maristela Stojić Vanja Bašić Kes Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab) Acta Clinica Croatica Migraine - Prevention,Treatment Calcitonin gene-related peptide (CGRP) Monoclonal antibody Guidelines Eptinezumab, Fremanezumab, Galcanezumab, Erenumab |
| title | Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab) |
| title_full | Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab) |
| title_fullStr | Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab) |
| title_full_unstemmed | Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab) |
| title_short | Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab) |
| title_sort | croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene related peptide cgrp eptinezumab fremanezumab and galcanezumab or the cgrp receptor erenumab |
| topic | Migraine - Prevention,Treatment Calcitonin gene-related peptide (CGRP) Monoclonal antibody Guidelines Eptinezumab, Fremanezumab, Galcanezumab, Erenumab |
| url | https://hrcak.srce.hr/file/474344 |
| work_keys_str_mv | AT davorjanculjak croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT damirpetravic croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT darijamahoviclakusic croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT arijanalovrencichuzjan croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT koraljkabacicbaronica croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT marijanabosnarpuretic croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT zlatkohucika croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT marinatitlic croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT zvonimirpopovic croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT zorantomic croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT maristelastojic croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab AT vanjabasickes croatianguidelinesforspecificpreventivetreatmentofmigrainewithmonoclonalantibodiestargetingcalcitoningenerelatedpeptidecgrpeptinezumabfremanezumabandgalcanezumaborthecgrpreceptorerenumab |